Liraglutide and tirzepatide are effective for weight loss but have a poorer safety profile and higher discontinuation rates due to adverse events
GCGR/GLP-1R agonist: Beta: 0.66, 95%CI: 0.440.88, P = 2.23 10 9
This includes hepatic steatosis, where 5% or more hepatocytes have macrovesicular steatosis in the absence of other causes of macrovascular steatosis in individuals who drink little or no alcohol, which is defined as less than 20 g/day for women and less than 30 g/day for men
The same active drug may appear under different brand names, with different FDA indications, doses, routes, and insurance rules
Insurance-reimbursed care becomes more important when treatment costs rise or long-term use is expected
PlexusDx provides medical consultation as part of the treatment process